|
Zhdanova I.V., Lynch H.J., Wurtman
R.J.,1997,
Melatonin: A Sleep-Promoting Hormone
Sleep Vol. 20, No. 10 pp 899-907
Summary: This review discusses the issue
of a dual effect of melatonin on sleep: acute sleep promotion that
typically occurs within one hour of administration, and the ability to
alter the phase of the underlying circadian pacemaker after a repeated
melatonin treatment. The authors suggest that both mechanisms are at
work, that they are complimentary, and that they may manifest jointly or
separately. The review provides some basic information on melatonin, an
overview of the literature, and the authors' experience in studying the
acute effects of melatonin treatment in humans of different age groups.
This review also illustrates the authors' cautious attitude toward
melatonin treatment that induces supraphysiologic circulating levels of
the hormone.
Wurtman R.J. 00,
Editorial: Age-Related Decreases in Melatonin Secretion-Clinical
Consequences. The Journal of Clinical Endocrinology and Metabolism Vol.
85, No 6 pp 2135-2136
Bubenik G.A., et al
1998, Prospects of Clinical Utilization of Melatonin. Biological Signals
and Receptors Vol. 7 pp 195-219
BioMedNet.com/karger
Abstract: This review summarizes the
present knowledge on melatonin in several areas on physiology and
discusses various prospects of its clinical utilization. Ever increasing
evidence indicates that melatonin has an immunohematopoietic role.
In animal studies, melatonin provided protection against
gram-negative septic shock, prevented stress induced
immunodepression, and restored immune function after a hemorrhagic
shock. In human studies, melatonin amplified the antitumoral
activity of interleukin-2. Melatonin has been proven as a powerful
cytostatic drug in vitro as well as in vivo. In the human clinical
field, melatonin appears to be a promising agent either as a
diagnostic or prognostic marker of neoplastic diseases or as a
compound used either alone or in combination with the standard
cancer treatment. Utilizationof melatonin for tratment of rhythm
disorders, such as those manifested in jet lag, shift work or
blindness, is one of the oldest and the most successful clinical
application of this chemical. Low doses of melatonin applied in
controlled release preparation were very effective in improving
the sleep latency, increasing the sleep efficiency and rising
sleep quality scores in elderly, melatonin deficient insomniacs.
In the cardiovascular system, melatonin seems to regulate the tone
of cerebral arteries; melatonin receptors in vascular beds appear
to participate in the regulation of body temperature. Heat loss
may be the principal mechanism in the initiation of sleepiness
caused by melatonin. The role of melatonin in the development of
migraine headaches is at present uncertain but more research could
result in new ways of treatment. Melatonin is the major messenger
of light dependent periodicity, implicated in the seasonal
reproduction of animals and pubertal development in humans.
Multiple receptor sites detected in brain and gonadal tissues of
birds and mammals of both sexes indicate that melatonin exerts a
direct effect on the vertebrate reproductive organs. In a clinical
study, melatonin has been used effectively as a female
contraceptive with little side effects. Melatonin is one of the
most powerful scavengers of free radicals. Because it easily
penetrates the blood brain barrier, this antioxidant may, in the
future, be used for the treatment of Alzheimer's and Parkinson's
diseases, stroke, nitric oxide, neurotoxicity and hyperbaric
oxygen exposure. Inthe digestive tract, melatonin reduced the
incidence and severity of gastric ulcers and prevented severe
symptoms of colitis,such as mucosal lesions and diarrhea. |
Geoffriau M., Brun J., Chazot G.,
Claustrat B.1998, The Physiology and Pharmacology of Melatonin in Humans
Hormone Research Vol. 49: pp 136-141
BioMedNet.com/karger
Abstract: Melatonin (MLT) is a methoxyindole secreted
principally by the pineal gland. It is synthesized at night under normal
environmental conditions. The endogenous rhythm of secretion is
generated by the suprachiasmatic nuclei and entrained by the light/dark
cycle. Light is able to both suppress or entrain MLT production on light
schedule. The nyctohemeral rhythm of this hormone can be determined by
repeated measurement of plasma or saliva MLT or urine sulfatoxy-MLT, the
main hepatic metabolite. MLT can be considered as the output (the hand)
of the endogenous clock. Since the regulating system follows a central
and sympathetic nervous pathway, an abnormality at any level could
unspecifically modify the MLT secretion, especially in patients with
sympathalgia or dysautonomia. MLT plays the role of an endogenous
zeitgeber on core temperature or sleep-wake cycle. Exogenous MLT is able
to influence the endogenous secretion of the hormone according to a
phase-response curve. There are practical implications for this property
in situations when biological rhythms are disturbed (jet-lag syndrome,
delayed sleep phase syndrome, insomnia in blind people, shift-work,
insomnia in elderly people). Improvement of pharmaceutical forms
(controlled release preparations) or development of MLT analogs could
lead to decisive progress.
Sack R.L., Hughes
R.J., Edgar D.M., Lewy A.J. 1997. Sleep-Promoting Effects of Melatonin:
At What Dose, in Whom, Under What Conditions, and by What Mechanisms?
Sleep Vol. 20 No.10 pp 908-915
Summary: Differing conclusions regarding
the sleep-promoting effects of melatonin may be the result of the broad
range of doses employed (0.1-2000mg), the differing categories
of subjects tested (normal subjects, insomniac patients,
elderly, etc.), and the varying times of administration (for
day-time vs. night-time sleep). We conclude that melatonin may
benefit sleep by correcting circadian phase abnormalities and/or
by a modest direct soporific effect that is most evident
following daytime administration to younger subjects. We
speculate that these effects are mediated by interactions
with specific receptors concentrated in the suprachiasmatic
nucleus (SCN) that result in resetting of the circadian
pacemaker an/or attenuation of an SCN dependent circadian
alerting process.
|